Liver Transplantation Results in Hepatocellular Carcinoma Patients With Immunosuppression Without Steroids
Not Applicable
Completed
- Conditions
- ImmunosuppressionHepatocellular CarcinomaLiver TransplantationPost-operative Complications
- Interventions
- Drug: a steroid-free immunosuppression protocol
- Registration Number
- NCT01137084
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Brief Summary
The purpose of this study was to evaluate the safety and efficacy of a steroid-free immunosuppression protocol in Hepatocellular Carcinoma (HCC) patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
- All liver transplantation patients with hepatocellular carcinoma in our center between Jan 2005 and Dec 2009 were potentially eligible for enrollment
Exclusion Criteria
- the recipient pass away within 3 month following up liver transplantation
- Inability to provide written informed consent prior to study entry
- acute rejection are treated only with steroids
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description a steroid immunosuppression protocol solu medrol - a steroid-free immunosuppression protocol a steroid-free immunosuppression protocol without steroid
- Primary Outcome Measures
Name Time Method patient and graft survival Over 12-month after liver transplantation patient and graft survival include surviral rate and recurrence-free survival rate
- Secondary Outcome Measures
Name Time Method Postoperative complications Over 12-month after liver transplantation Postoperative complications include acute rejection, infection, metabolic complications and hepatitis B-virus recurrence.
Trial Locations
- Locations (1)
Shanghai First People's Hospital
🇨🇳Shanghai, Shanghai, China